• Elekta reported new phase 2 data already presented at ASTRO on Leksell Gamma Knife use in patients with up to 50 brain metastases.
• The study found memory performance remained favorable two months after treatment, supporting a cognitive-sparing profile for focal radiosurgery.
• Investigators saw no meaningful difference in time to cognitive decline between patients with 21 to 50 tumors versus 5 to 20.
• Results could broaden the addressable market for Gamma Knife in multi-metastasis cases, challenging reliance on whole-brain radiation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elekta AB published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.